Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADS-5102, · 1 trial · 2 indications
The incidence of treatment-emergent adverse events was used as the measure for long-term safety and tolerability of ADS-5102.
| Arm | Type | Description |
|---|---|---|
| ADS-5102, 274 mg | EXPERIMENTAL | 274 mg ADS-5102, administered once daily at bedtime for up to 52 weeks |
| Name | Type | Description |
|---|---|---|
| ADS-5102, 274 mg | DRUG | Oral capsules |
Inclusion Criteria: * Signed a current IRB-approved informed consent form * Successful completion of a prior double blind study of ADS-5102 in patients with MS walking impairment. Exclusion Criteria: * Based on the judgment of the investigator or Medical Monitor, participation in the study would ...